de State Street BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 152 M | Comprar |
15,191,098
+2,982,738
| +24% | +USD 27 M | ﹤0.01% | 1233 |
|
|
2026
Q1 | USD 116 M | Comprar |
12,208,360
+1,135,149
| +10% | +USD 8.82 M | ﹤0.01% | 1297 |
|
|
2025
Q4 | USD 86.4 M | Comprar |
11,073,211
+1,265,773
| +13% | +USD 9.15 M | ﹤0.01% | 1440 |
|
|
2025
Q3 | USD 74.4 M | Comprar |
9,807,438
+1,302,046
| +15% | +USD 10.8 M | ﹤0.01% | 1521 |
|
|
2025
Q2 | USD 76.2 M | Comprar |
8,505,392
+691,988
| +9% | +USD 6.44 M | ﹤0.01% | 1458 |
|
|
2025
Q1 | USD 58.6 M | Comprar |
7,813,404
+314,437
| +4% | +USD 2.54 M | ﹤0.01% | 1561 |
|
|
2024
Q4 | USD 56.4 M | Vender |
7,498,967
-1,350,621
| -15% | -USD 10.3 M | ﹤0.01% | 1653 |
|
|
2024
Q3 | USD 67.3 M | Vender |
8,849,588
-497,211
| -5% | -USD 3.78 M | ﹤0.01% | 1552 |
|
|
2024
Q2 | USD 57.8 M | Vender |
9,346,799
-8,130,545
| -47% | -USD 44.9 M | ﹤0.01% | 1594 |
|
|
2024
Q1 | USD 88.8 M | Comprar |
17,477,344
+4,700,341
| +37% | +USD 26.4 M | ﹤0.01% | 1385 |
|
|
2023
Q4 | USD 76.5 M | Comprar |
12,777,003
+2,310,625
| +22% | +USD 13.4 M | ﹤0.01% | 1467 |
|
|
2023
Q3 | USD 74.1 M | Vender |
10,466,378
-1,797,591
| -15% | -USD 12.9 M | ﹤0.01% | 1377 |
|
|
2023
Q2 | USD 86.3 M | Comprar |
12,263,969
+874,346
| +8% | +USD 7.02 M | ﹤0.01% | 1323 |
|
|
2023
Q1 | USD 95 M | Comprar |
11,389,623
+262,762
| +2% | +USD 2.53 M | 0.01% | 1226 |
|
|
2022
Q4 | USD 128 M | Comprar |
11,126,861
+1,722,614
| +18% | +USD 21.5 M | 0.01% | 1017 |
|
|
2022
Q3 | USD 118 M | Vender |
9,404,247
-1,600,556
| -15% | -USD 20.6 M | 0.01% | 1009 |
|
|
2022
Q2 | USD 116 M | Comprar |
11,004,803
+3,542,051
| +47% | +USD 36.5 M | 0.01% | 1056 |
|
|
2022
Q1 | USD 121 M | Vender |
7,462,752
-786,277
| -10% | -USD 12.6 M | 0.01% | 1157 |
|
|
2021
Q4 | USD 114 M | Comprar |
8,249,029
+1,143,706
| +16% | +USD 15.1 M | 0.01% | 1191 |
|
|
2021
Q3 | USD 102 M | Comprar |
7,105,323
+852,551
| +14% | +USD 13.4 M | 0.01% | 1244 |
|
|
2021
Q2 | USD 98.9 M | Vender |
6,252,772
-1,056,044
| -14% | -USD 14.3 M | 0.01% | 1298 |
|
|
2021
Q1 | USD 74.3 M | Vender |
7,308,816
-3,748,163
| -34% | -USD 38.6 M | ﹤0.01% | 1457 |
|
|
2020
Q4 | USD 82.4 M | Vender |
11,056,979
-5,126,994
| -32% | -USD 26.4 M | 0.01% | 1296 |
|
|
2020
Q3 | USD 55.6 M | Comprar |
16,183,973
+605,578
| +4% | +USD 2.6 M | ﹤0.01% | 1378 |
|
|
2020
Q2 | USD 74.2 M | Comprar |
15,578,395
+9,832,343
| +171% | +USD 39.3 M | 0.01% | 1165 |
|
|
2020
Q1 | USD 11.5 M | Comprar |
5,746,052
+253,109
| +5% | +USD 697 k | ﹤0.01% | 2197 |
|
|
2019
Q4 | USD 19 M | Comprar |
5,492,943
+631,167
| +13% | +USD 1.59 M | ﹤0.01% | 2168 |
|
|
2019
Q3 | USD 13.9 M | Vender |
4,861,776
-1,783,941
| -27% | -USD 5.55 M | ﹤0.01% | 2300 |
|
|
2019
Q2 | USD 25.2 M | Comprar |
6,645,717
+3,135,675
| +89% | +USD 18.9 M | ﹤0.01% | 1960 |
|
|
2019
Q1 | USD 28.6 M | Comprar |
3,510,042
+713,082
| +25% | +USD 6.11 M | ﹤0.01% | 1815 |
|
|
2018
Q4 | USD 22.6 M | Vender |
2,796,960
-598,741
| -18% | -USD 4.66 M | ﹤0.01% | 1895 |
|
|
2018
Q3 | USD 25.9 M | Vender |
3,395,701
-281,703
| -8% | -USD 1.89 M | ﹤0.01% | 1993 |
|
|
2018
Q2 | USD 21.1 M | Vender |
3,677,404
-827,310
| -18% | -USD 4.55 M | ﹤0.01% | 2099 |
|
|
2018
Q1 | USD 21.5 M | Comprar |
4,504,714
+610,167
| +16% | +USD 3.14 M | ﹤0.01% | 1997 |
|
|
2017
Q4 | USD 19.1 M | Comprar |
3,894,547
+926,962
| +31% | +USD 4.49 M | ﹤0.01% | 2079 |
|
|
2017
Q3 | USD 15.5 M | Vender |
2,967,585
-941,428
| -24% | -USD 4.82 M | ﹤0.01% | 2189 |
|
|
2017
Q2 | USD 21.7 M | Comprar |
3,909,013
+1,636,909
| +72% | +USD 10 M | ﹤0.01% | 1930 |
|
|
2017
Q1 | USD 19.1 M | Comprar |
2,272,104
+179,216
| +9% | +USD 1.25 M | ﹤0.01% | 1972 |
|
|
2016
Q4 | USD 13.2 M | Comprar |
2,092,888
+744,580
| +55% | +USD 3.87 M | ﹤0.01% | 2185 |
|
|
2016
Q3 | USD 5.94 M | Comprar |
1,348,308
+8,960
| +0.7% | +USD 35.8 k | ﹤0.01% | 2463 |
|
|
2016
Q2 | USD 3.8 M | Vender |
1,339,348
-3,984
| -0.3% | -USD 12.4 k | ﹤0.01% | 2756 |
|
|
2016
Q1 | USD 3.8 M | Vender |
1,343,332
-771,436
| -36% | -USD 3.42 M | ﹤0.01% | 2698 |
|
|
2015
Q4 | USD 21.8 M | Vender |
2,114,768
-1,037,545
| -33% | -USD 10.3 M | ﹤0.01% | 1651 |
|
|
2015
Q3 | USD 35.9 M | Vender |
3,152,313
-57,895
| -2% | -USD 773 k | ﹤0.01% | 1354 |
|
|
2015
Q2 | USD 47.9 M | Vender |
3,210,208
-131,004
| -4% | -USD 1.49 M | 0.01% | 1299 |
|
|
2015
Q1 | USD 30.2 M | Comprar |
3,341,212
+550,777
| +20% | +USD 5.7 M | ﹤0.01% | 1549 |
|
|
2014
Q4 | USD 33.9 M | Comprar |
2,790,435
+458,369
| +20% | +USD 5.06 M | ﹤0.01% | 1433 |
|
|
2014
Q3 | USD 22.8 M | Comprar |
2,332,066
+84,612
| +4% | +USD 1.04 M | ﹤0.01% | 1646 |
|
|
2014
Q2 | USD 28.7 M | Comprar |
2,247,454
+609,035
| +37% | +USD 5.93 M | ﹤0.01% | 1563 |
|
|
2014
Q1 | USD 17.3 M | Comprar |
1,638,419
+1,579,735
| +2,692% | +USD 16.8 M | ﹤0.01% | 1887 |
|
|
2013
Q4 | USD 446 k | Comprar |
58,684
+9,700
| +20% | +USD 61.4 k | ﹤0.01% | 3371 |
|
|
2013
Q3 | USD 357 k | Comprar |
48,984
+7,700
| +19% | +USD 39.1 k | ﹤0.01% | 3385 |
|
|
2013
Q2 | USD 64 k | Comprar |
+41,284
| Nuevas | +USD 71.2 k | ﹤0.01% | 3413 |
|
Otros fondos que tienen BCRX en su cartera
Posición de State Street en BCRX: resumen de T2 2026
State Street aumentó su participación en BioCryst Pharmaceuticals (BCRX) en 24% durante T2 2026, al comprar aproximadamente USD 27 M y elevar la posición a 15,191,098 acciones con un valor de USD 152 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1233.
State Street reportó por primera vez una posición en BCRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, State Street tenía 15,191,098 acciones de BioCryst Pharmaceuticals con un valor de USD 152 M.
- State Street compró 2,982,738 acciones de BioCryst Pharmaceuticals en T2 2026, por un monto estimado de USD 27 M.
- BioCryst Pharmaceuticals representó ﹤0.01% de la cartera de State Street en T2 2026 y fue su posición número 1233.
- State Street reportó por primera vez una posición en BioCryst Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de State Street correspondiente a T2 2026, presentado el 7 ago 2026.